University of Virginia, 2000 - $13,769
Millions of people are diagnosed with life-threatening allergies each year, and in extreme cases these allergies can cause a deadly anaphylactic response. To combat anaphylaxis in an emergency situation, allergic individuals carry a life-saving injectable dose of epinephrine; however, epinephrine injectors currently on the market are too bulky and a hassle to carry, and as a result less than half the people who should carry an injector on them at all times actually do so. To answer this problem, the EpiCard E-Team, now formally incorporated as Intelliject, Inc., has invented an automatic epinephrine injecting system that is credit-card sized and easy to use. The EpiCard can be carried almost anywhere -- in the user's purse, wallet, or pocket -- and is efficient and safe.
The Virginia-based company has now received nearly $13 million in funding from various sources. Visit intelliject.com for more information.
- In 2009, Intelliject announced an exclusive license worth $230 million with Sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, Sanofi-aventis U.S. shall be responsible for manufacturing and commercialization. Intelliject will be responsible for the on-going development and for obtaining U.S. regulatory approval and has retained certain co-promotion rights in the territory.
- February 2012: Evan and Eric Edwards and their product, now called Auvi-Q, were featured in the NY Times.
- About NCIIA
- Meet our grantees
- For students
- For faculty
- Specialty training programs
- Annual conference
- NCIIA in the news
- Contact us